Get reliable laboratory findings – how to recognize the deceptive effects of angiotensin-converting enzyme inhibitor therapy in the laboratory diagnostics of sarcoidosis?

Szabó, Attila Ádám and Enyedi, Enikő Edit and Altorjay, István Tibor and Hajnal, Péter and Pintér, Tamés Bence and Mányiné, Siket Ivetta and Váradi, Csongor and Bányai, Emese and Tóth, Attila and Papp, Zoltán and Fagyas, Miklós (2024) Get reliable laboratory findings – how to recognize the deceptive effects of angiotensin-converting enzyme inhibitor therapy in the laboratory diagnostics of sarcoidosis? CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 62 (7). pp. 1393-1401. ISSN 1434-6621

Preview	Text 10.1515_cclm-2023-1288.pdf - Published Version Available under License Creative Commons Attribution. Download (1MB) | Preview
Preview	Text Get reliable laboratory findings – how to recognize the deceptive effects of angiotensin-converting enzyme inhibitor therapy in the laboratory diagnostics of sarcoidosis.pdf Available under License Creative Commons Attribution. Download (1MB) | Preview

Abstract

Objectives: Serum angiotensin-converting enzyme (ACE) is the only biomarker routinely used in the laboratory diagnostics of sarcoidosis, and ACE inhibitor (ACEi) drugs are among the most prescribed drugs worldwide. Taking ACEi can mislead medical teams by lowering ACE activity, delaying diagnosis and giving a false impression of disease activity of sarcoidosis. We aimed to develop a simple method to detect the presence of ACEi drugs in samples, to investigate the ACEi medication-caused interference and consequences in a retrospective study. Methods: ACE activity and the level of ACE inhibition were determined for 1823 patients with suspected sarcoidosis.These values were compared with the therapeutic information at the first and follow-up visits. Results: A total of 302 patients had biochemical evidence of an ACEi drug effect during diagnostic ACE activity testing. In their case, ACE activity was significantly lower (median(IQR): 4.41 U/L(2.93–6.72)) than in patients not taking ACEi (11.32 U/L(8.79–13.92), p<0.01). In 62 sarcoidosis patients, the ACEi reduced ACE activity to the reference range or below. Only in 40 % of the cases was the medication list recorded in the outpatient chart and only in 3 cases was low ACE activity associated with ACEi use. 67 % of the repeated ACE activity measurements were also performed during ACEi therapy. Conclusions: Our study revealed that the use of ACEi is common in patients with suspected sarcoidosis. The ACE activity lowering effect of ACEi drugs may escape the attention of medical teams which can lead to diagnostic errors and unnecessary tests. Nevertheless, these pitfalls can be avoided by using a method suggested by our team.

Actions (login required)

Edit Item